New drug combo tested to halt rare, spreading tumors
NCT ID NCT03950609
Summary
This study is testing whether two oral medications, lenvatinib and everolimus, can help control advanced carcinoid tumors that have spread and cannot be surgically removed. The trial aims to see if the drug combination can shrink tumors or stop their growth, and to monitor side effects. It involves 36 patients with this rare type of neuroendocrine cancer who have seen their disease progress.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.